Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence - PubMed
5 hours ago
- #Filgotinib
- #Janus kinase inhibitor
- #Rheumatoid Arthritis
- Filgotinib (FIL) is a Janus kinase 1-preferential inhibitor and a targeted synthetic DMARD approved for rheumatoid arthritis (RA) after methotrexate (MTX) failure.
- Randomized controlled trials (RCTs) show FIL, especially 200 mg with MTX, rapidly reduces disease activity, pain, and fatigue, improves function, and minimizes long-term radiographic progression, sometimes outperforming adalimumab.
- Safety profiles of FIL are similar to MTX and adalimumab over short and long terms (>8 years), with high treatment persistence rates in clinical trials.
- Real-world evidence supports FIL's effectiveness and safety as demonstrated in RCTs, reinforcing its role as a therapeutic option in RA management.
- Guidelines recommend starting with 200 mg FIL ± MTX; a 100 mg dose is advised for elderly patients, those at risk of thromboembolism, cardiovascular events, malignancy, or with renal impairment.
- Future studies are expected to provide more insights into FIL's long-term real-world effectiveness and safety, including joint outcomes.